Last reviewed · How we verify

NCT05678790

Mitochondrial Membrane Protein Neurodegeneration (MPAN)

Completed NA Last updated 28 September 2023
What this trial tests

NA trial testing Passive Stretching in MPAN in 2 participants. Completed in 28 September 2023.

Timeline
1 April 2023
Primary endpoint
28 September 2023
28 September 2023

Quick facts

Lead sponsorKirsehir Ahi Evran Universitesi
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment2
Start date1 April 2023
Primary completion28 September 2023
Estimated completion28 September 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kirsehir Ahi Evran Universitesi — full company profile →

Who can join

Adults 9 to 14, male only, with MPAN. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this case study was to investigate the effects of therapeutic intervention in 9- and 12-year-old brothers with MPAN. The main hypothesis it aims to answer is: -A 6-week balance and coordination focused rehabilitation program improves independence and gait parameters in patients with MPAN.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Rehabilitation for Mitochondrial Membrane Protein-Related Neurodegeneration: A Case Study.
    Özçelep ÖF, Turhan A, Fi Dan S, Kandemir S. · · 2023 · PMID 38222195 · DOI 10.7759/cureus.50540

Verify or expand the search:

Other trials of Passive Stretching

Trials testing the same drug.

Other Kirsehir Ahi Evran Universitesi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05678790.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing